Anti-GBM disease
Conditions
Interventions
Participating patients will be treated with daily immunoadsorption, instead of
plasma exchange, until anti-GBM titres are undetectable. All other aspects of
the treatment (e.g. immunosuppressive tre
Glomerulonephritis
Renal failure
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Acute renal failure due to anti-GBM glomerulonephritis with or without accompanying pulmonary involvement. Eligible patients must have a clinical picture met rapidly progressive glomerulonephritis in combination with one of the following: 1. serological evidence of circulating anti-GMB antibodies (Dotblot, Phadia, ELISA); 2. Renal biopsy with necrotising glomerulonephritis with linear fluorescence for IgG along the GBM. Notably, in case of serological evidence of circulating anti-GBM antibodies, a renal biopsy is not mandatory for inclusion in this study.
Exclusion criteria
Exclusion criteria: There are no exclusion criteria. Because of the severity of the disease also patients with a short life expectancy will be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma levels of anti-GBM before and after each immunoadsorption treatment. The main study parameter is the number of days that anti-GBM antibody titre is above a toxic level, defined as >30 ELISA units. Courses of anti-GBM titres will be compared with an historical cohort of patients with anti-GBM disease treated with plasma exchange. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Tolerability and adverse events of immunoadsorption. 2. Logistic feasibility. We will specifically assess the time between diagnosis and start of the first immunoadsorption treatment. 3. Costs: both personnel requirements and material costs. | — |
Countries
The Netherlands
Outcome results
None listed